Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
D000609:Aminoacridines / Q000627:therapeutic use*; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000609:Aminoacridines; D000970:Antineoplastic Agents; D009943:Organophosphorus Compounds; D000677:Amsacrine; D001224:Aspartic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid